more than a week apart. The lowest value is then used to
determine which quartile the person is in. Even this approach
may be insufficient to correct for the variability.

There are outstanding laboratory problems with use of
hs-CRP. Not all assays produce identical results. No laboratory
has the resources to determine its own reference ranges, so
transportability of results between assays is obviously of great
importance in defining the concentrations that relate to the
different quartiles of basal CRP concentration. At the present
time it appears undesirable to attempt to use hs-CRP in
individual risk stratification.

REFERENCES
1. The Joint European Society of Cardiology/American College of Cardiology
   Committee. Myocardial infarction redefined – a consensus document of
   the Joint European Society of Cardiology/American College of Cardiology
   Committee for the redefinition of myocardial infarction. J Am Coll
2. Schroeder JS, Lamb IH, Hu M. Do patients in whom myocardial infarction
   has been ruled out have a better prognosis after hospitalization than those
4. Pennell JP. Optimizing medical management of patients with pre-end-
5. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic
6. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for
   global risk assessment in the primary prevention of cardiovascular disease.

7. Campbell B, Radrick T, Flatman R, Kanowski D. Limited clinical utility
   of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem

FURTHER READING
Ridker PM, Rifai N, Rosso L, Buring JE, Cook NR. Comparison of C-reactive
protein and low-density lipoprotein cholesterol levels in the prediction of first
Ewald B. B-type natriuretic peptide: a new diagnostic tool for congestive heart

Conflict of interest: none declared

Self-test questions
The following statements are either true or false (answers on page 95)
5. Ectopic production of cardiac troponins reduces
   their usefulness in assessing acute coronary
   syndromes.
6. Measuring high sensitivity C-reactive protein
   provides an accurate prediction of an individual’s
   risk of cardiovascular disease.

National Prescribing Service Ltd (NPS) information hotlines

NPS operates two hotlines providing health professionals and the community with information about medicines.

Therapeutic Advice and Information Service (TAIS): 1300 138 677
For general practitioners, pharmacists and other
community-based health professionals

The Therapeutic Advice and Information Service (TAIS) has been in operation for three years and to date has received more than 15 000 enquiries. The majority of callers were community pharmacists (48%) and general practitioners (35%). The most commonly asked questions were about drug interactions, adverse reactions and therapeutic options.

Information is provided by expert drug information specialists. The service operates Australia-wide, Monday to Friday 9am to 7pm (EST) for the cost of a local call.

Medicines Line: 1300 888 763
For consumers

TAIS is complemented by Medicines Line, a medicines information hotline for consumers. Medicines Line was launched in September 2002 and receives approximately 1000 calls every month.

Statistics show that most callers are females aged 24–64; 25% of callers ask for information on behalf of a child, partner or parent. Questions often reflect what is being reported in the media at the time and are focused on adverse reactions, interactions, and to a lesser extent the mechanisms of action of medicines. Questions are most commonly related to antidepressants, antihypertensives and complementary medicines.

Information is provided by expert drug information specialists. The service operates Australia-wide, Monday to Friday 9am to 6pm (EST) for the cost of a local call.